This work examines the capacity of Naringin and Rutin to influence the DNA damage response (DDR) pathway by investigating their interactions with key DDR proteins, including PARP-1, ATM, ATR, CHK1, and WEE1. Through a combination of in silico molecular docking and in vitro evaluations, we investigated the cytotoxic and genotoxic effects of these compounds on MDA-MB-231 cells, comparing them to normal human fibroblast cells (2DD) and quiescent fibroblast cells (QFC). The research found that Naringin and Rutin had strong affinities for DDR pathway proteins, indicating their capacity to specifically regulate DDR pathways in cancer cells. Both compounds exhibited preferential cytotoxicity towards cancer cells while preserving the vitality of normal 2DD fibroblast cells, as demonstrated by cytotoxicity experiments conducted at a dose of 10 µM. The comet experiments performed particularly on QFC cells provide valuable information on the genotoxic impact of Naringin and Rutin, highlighting the targeted initiation of DNA damage in cancer cells. The need to use precise cell models to appropriately evaluate toxicity and genotoxicity is emphasized by this discrepancy. In addition, ADMET and drug-likeness investigations have emphasized the pharmacological potential of these compounds; however, they have also pointed out the necessity for optimization to improve their therapeutic profiles. The antioxidant capabilities of Naringin and Rutin were assessed using DPPH and free radical scavenging assays at a concentration of 10 µM. The results confirmed that both compounds have a role in reducing oxidative stress, hence enhancing their anticancer effects. Overall, Naringin and Rutin show potential as medicines for modulating the DDR in cancer treatment. They exhibit selective toxicity towards cancer cells while sparing normal cells and possess strong antioxidant properties. This analysis enhances our understanding of the therapeutic uses of natural chemicals in cancer treatment, supporting the need for more research on their mechanisms of action and clinical effectiveness.
Artificial intelligence–assisted prompting is accelerating target discovery by integrating multi-omics and network data. Using Swalife PromptStudio, we identify CLIC1, a redox-regulated chloride channel and metamorphic protein linking cytoskeletal, redox, and metabolic modules. Multi-omics analyses show its consistent overexpression in cancers and neuroinflammatory diseases, correlating with poor prognosis. GWAS and ClinVar highlight CLIC1 as a modifier of immune traits and cancer susceptibility, while somatic amplifications confirm its oncogenic role. Network analysis positions it as a high-centrality hub overlapping with cancer hallmarks. Its benign germline pathogenicity profile suggests low toxicity risk, supporting therapeutic targeting. These findings validate prompt-driven approaches for assembling actionable insights and establish CLIC1 as a promising, polypharmacological target across disease contexts.
Breast cancer remains a significant global health concern, ranking as the second leading cause of cancer-related mortality among women. The increasing incidence necessitates the development of more efficacious therapeutic strategies. This study evaluates the potential of a novel Wheatgrass-Tulsi Self-Emulsifying Drug Delivery System (WT-SEDDS) as an anticancer agent through comprehensive in vitro and in vivo investigations. The antioxidant capacity of WT-SEDDS was assessed using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay at concentrations ranging from 50 to 400 µg/mL. Cytotoxicity was evaluated via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on Michigan Cancer Foundation-7 (MCF-7) breast cancer cells and predipocyte-derived mouse embryonic fibroblasts (normal cell line) at concentrations of 12.5-100 µg/mL. Antimitotic activity was investigated using earthworm regeneration model at WT-SEDDS concentrations of 100, 500, and 1000 µg/mL. Acute oral toxicity was assessed following OECD Guideline 425 [23]. In vivo studies utilized a 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer model in Sprague Dawley rats. WT-SEDDS and tamoxifen treatments were compared for their effects on tumor incidence, volume, and burden. Hematological parameters (hemoglobin, red blood cell count) and oxidative stress markers (superoxide dismutase, reduced glutathione, malondialdehyde) were quantified. Histopathological analysis was performed to confirm the therapeutic efficacy. Results demonstrated that WT-SEDDS exhibited significant antioxidant, cytotoxic, and antimitotic properties in vitro, with no acute oral toxicity observed. In vivo, WT-SEDDS treatment significantly reduced tumor progression and modulated hematological and oxidative stress parameters comparable to tamoxifen. Histopathological findings corroborated the therapeutic potential of WT-SEDDS against DMBA-induced mammary carcinogenesis. This study provides compelling evidence for the anticancer efficacy of WT-SEDDS, warranting further investigation as a potential therapeutic agent for breast cancer management.
The integration of artificial intelligence (AI) in biomedical research has revolutionized data analysis, yet researchers continue to face challenges in efficiently identifying and interpreting complex relationships among herbs, diseases, and protein targets. Traditional literature review and database exploration methods are time-intensive, fragmented, and often fail to capture the multi-dimensional nature of biological interactions involved in herbal therapeutics.To address this gap, the Swalife AI-Powered Network Analysis Tool has been developed as an intelligent platform that automates literature mining, data integration, and network visualization. By combining data from PubMed and UniProt, the tool constructs herb-disease-protein interaction networks, enabling users to uncover potential molecular targets and biological pathways relevant to drug discovery, systems pharmacology, and personalized medicine.The tool allows users to input disease and herb parameters to retrieve related scientific articles, identify target proteins, and visualize interactive biological networks. Its features such as downloadable data outputs and graphical mapping facilitate in-depth exploration of molecular mechanisms underlying herbal actions. The platform ultimately accelerates hypothesis generation, enhances research efficiency, and bridges the gap between traditional medicine and modern molecular biology.
Discovering the molecular mechanisms of DNA damage response pathways has led to new therapeutic approaches in oncology. Our study optimized DNA damage- targeting molecules naringin and rutin in breast cancer cells. Our study involved MTT assays for the detection of its toxicity and proliferative activity in breast cancer cells and normal cancer cells. Our studies determined the molecules' antioxidant properties using the DPPH assay. The role in reducing free radicals has been evaluated using a variety of free radical scavenging activity assays. Further evaluation of the molecules was carried out by high alkaline comet assay (pH > 13) to test for genotoxicity. Human Dermal Fibroblast cells (2DD) (1x105 cells/ml) and breast cancer cells (MDA-MB-231) were pre-incubated with Naringin and Rutin (10 µM) for one hour. In normal cells, rutin and naringin molecules do not cause genotoxicity, but they cause DNA damage in breast cancer cells when they are diluted to 10µM. The results from our study indicate that both molecules cause 60–70% DNA damage in breast cancer cells.